period was recorded and defined as a system containing more than one separate shunt system or one containing more then one proximal or distal component, respectively. The number of previous shunt therapy-related failures and the subcategory of infections, were determined. Shunt failure and infection were defined in accordance with the guidelines established in the shunt design trial. 6 Information regarding the outcome of death was obtained from the hospital charts, physician office records, autopsy reports and the Registrar General of Canada. The date of death and its underlying cause were determined from these records. The cause of death was divided into the following: 1) related to shunt malfunction; 2) not related to the shunt; 3) a preestablished DNR; and 4) could not be determined. A direct cause of shunt-related death was defined as a malfunction secondary to obstruction, infection, overdrainage, or loculation of ventricles. Death not related to the shunt was defined as that caused by an underlying disease process (not related to hydrocephalus) and/or autopsy evidence of a patent noninfected shunt. Despite review of the patient's chart, outpatient records, files from family doctor, autopsy reports, and information from the Registrar General, the exact cause of death could not be determined in some patients.
Statistical analysis included descriptive statistics regarding patient characteristics, shunt features, and the number/types of previous failures. The Kaplan-Meier survival method was used to ascertain the overall patient survival (from the time of the initial shunt insertion to death and from birth to death). Patient age, type of shunt (multiple and/or complex), number of failures, and number of shunt infections were analyzed as risk factors for death (cases of pseudotumor cerebri and arachnoid cyst were also excluded). The last two covariates (number of failures and infections) and age were maintained as continuous variables. Univariate analysis was performed using the log-rank statistics. Multivariate analysis included use of Cox regression to determine the significance of the various risk factors in predicting the outcome of death. Hazard ratios, 95% CIs, and probability values were calculated. A probability value of less than 0.05 was chosen as the level of significance. The statistical analysis was performed using SAS (SAS Institute, Inc., Cary, NC) and SPSS (SPSS, Inc., Chicago, IL) software.
Results
The study consisted of 907 (486 male and 421 female) patients. Overall, 124 patients died during the study period. The most common presenting conditions requiring CSF shunt treatment included myelomeningocele (114 cases), tumor (190 cases), and IVH (114 cases) with death in 7.9% (15 cases), 32.6% (62 cases), and 3.5% (four cases), respectively ( Table 1 ). The nonhydrocephalic causes of CSF diversion included pseudotumor cerebri in 11 patients and arachnoid cyst in 57 patients, with no deaths in the former and three in the latter. The analysis was restricted to patients without tumor.
Overall characteristics varied among patients who survived and those who died ( Table 2 ). The median age at the time of the initial shunt insertion was similar between the two groups (32 days in those who lived compared with 36 days in those who died). The mean and median weight was higher in the surviving patients. Patients who died were more likely categorized as ASA Class 3 2 or higher (72%) than those who lived (43%); fewer of the former (69.4%) received preoperative antibiotic agents than the latter (81.5%). Similarities between the two groups were found with respect to the shunt aspects (type, location, side of placement). Slightly more flow-regulated shunts were used in patients who survived (10%) than those who died (6.8%). Fewer multiple and complex shunts had been placed in surviving patients. In 55.3% of the patients who survived, the shunt failed, and 18.5% of these sustained a shunt-related infection. Of the patients who died, previous or concurrent shunt failure had occurred in 58.1%, with 19.3% due to infection.
Of the 717 patients evaluated, 62 (8.6%) died during the 11-year study period. Analysis revealed survival rates of 95.6, 91.2, and 87.6% at 1, 5, and 10 years, respectively (from time of initial shunt insertion to death) ( Fig. 1 left) . The 1-, 5-, and 10-year survival rates were 92.6, 89.4, and 87.3%, respectively, birth to death (Fig. 1 right) . Assessment of the causes of death among the aforementioned patients showed that of the 62 patients, only 10 died directly due to the shunt. In 21 cases the cause of death was unrelated to the shunt. Causes of death not related to the shunt included pneumonia, severe congenital malformation in cases not treated aggressively (tetralogy of Fallot, Fanconi sydrome, Walker-Warburg syndrome), vein of Galen aneurysm rupture, and sudden death (without imaging or autopsy evidence of shunt malfunction). In 17 patients, a serious underlying disease or medical problem, including major brain or other organ system malfunction, seizure disorder, and repeated aspiration, made it difficult to determine the exact cause of death. Every attempt was made to ascertain whether shunt therapy was the cause of death because not all children died in the hospital or underwent autopsy evaluation. Of 62 patients, DNR status and/or severe congenital malformations were present in 25 ( Table 3 ). The decision to confer DNR status was related to the patient's underlying congenital or medical problem and not to intractable shunt failure.
We analyzed possible factors contributing to death. Multivariate analysis involving Cox regression revealed that the number of infections had a statistically significant contribution (p = 0.043) to death (hazard ratio 1.66, 95% CI 1.02-2.72) (Table 4) . Age, the presence of multiple or complex shunts, and the number of failures were not found to contribute to death. The cause of death within each cause-specific category of hydrocephalus could not be determined separately because of the small sample size in each cell.
Discussion
Long-term outcome following CSF shunt placement in patients with hydrocephalus has been evaluated in numerous studies since the 1960s. 1, 3, 4, [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [21] [22] [23] [24] [25] To date, no authors have provided an analysis-based evaluation of the risk factors associated with death in shunt-treated patients. The present study was performed to determine the causes of death in a large cohort of patients with hydrocephalus who had been followed very closely at a single institution. Every effort was made to determine the cause of death by reviewing hospital records, contacting family doctors, searching the Registrar General's database of Ontario, and reviewing autopsy records. Despite this intensive search, it was often difficult to ascertain the exact cause of death. Shunt-related infection was the only contributing factor that was evident.
Mortality rates in patients with hydrocephalus requiring CSF diversionary procedures vary from 1.05 to 38%. 1, 3, 4, 7, [10] [11] [12] 14, 18, 19, 21, [23] [24] [25] In early reports investigators focused on comparing data between treated and untreated patients. The initially high mortality rates have continued to decline because of advances in shunt technology and refinement in treating the primary disease. In more recent studies investigators have focused on mortality rates in the various hydrocephalic populations. 16, 22, 24 Resch, et al., 22 reported four deaths in 26 patients with IVH requiring CSF shunt placement. In our study the mortality rate of 3.5% was lower in the 114 patients with IVH. Published mortality rates in patients with myelomeningocele have been as high as 39% and have continued to decline. In our study this rate was 7.9%, which is comparable to that reported by Staal, et al. 16, 24 We found that the mortality rates were high in certain nontumor-related causes of hydrocephalus: 18.8% in cases of encephalocele, 14.3% in those of Dandy-Walker malformation, 15.8% in those of craniofacial disorder, 14.3% in those of posttraumatic hydrocephalus, and 13.2% in cases of congenital hydrocephalus.
Of the 717 patients with hydrocephalus unrelated to tumor, 62 deaths ocurred during the 11-year study period. Five-year survival was 91.7%. In only 10 (22%) of 45 cases the cause of death was related to malfunction of the shunt (in patients in whom a cause of death could be identified). The results of other studies also indicate that a high incidence of mortality is not directly related to shunt malfunction. 13, 14, 17 The cause of death in shunt-treated patients with hydrocephalus has not been analyzed in the past. Iskandar, et al., 11 reported 11 deaths in 357 patients in whom shunt therapy was initially instituted between 1990 and 1996 for nontumor-related hydrocephaus. All patients died of hydrocephalus or hydrocephalus-related causes; cause of death was not explained. In another recent retrospective study, investigators followed 155 patients after placement of a VP shunt. 4 Twenty-three patients died, nine of whom harbored a neoplasm. Fourteen of 128 deaths were noted in patients without tumor. The authors provided a descriptive summary of the cause of death, stating that the precise cause was supported this view when they concluded that shunt infections contributed to 20% of deaths, whereas shunt malfunction led to 30% and pulmonary emboli to 7% of deaths. Lumenta and Skotarczak, 15 reporting on 233 patients in whom shunts were placed for congenital hydrocephalus, noted 32 deaths, of which 12 were associated with infections. We tested these previous hypotheses by analyzing 717 pediatric patients followed for 11 years.
The overall rate of shunt infection in patients who survived was 18.5%, whereas that in those who died was 19.3%. This reflects the infection rate per patient during their lifetime (thus not restricting to the initial procedure). The infection rate per procedure (that is, following the first shunt insertion) was 10.9% (78 of 717 cases). This is in keeping with previously reported infection rates of 7 to 9.8%. 5, 7, 20 Multivariate analysis revealed a statistically significant association between all deaths and a history of shunt infection, which supports previous hypotheses. Of note, all deaths (rather than deaths due only to shunt malfunction) were used as the outcome variable. There was not enough evidence to support an increased risk of death due to variation in age, presence of multiple shunt parts, presence of complex shunt, and a history of increased shunt failures.
Conclusions
Advances in the management of hydrocephalus, including diagnostic imaging, shunt devices, and medical therapy, have resulted in a progressive decrease in the morbidity and mortality rates in shunt-treated patients with hydrocephalus, and findings in long-term follow-up studies confirm a decline in mortality over time. The mortality rate, however, remains significant. Shunt infections, as a probable cause of an increased mortality rate, need to be reduced. difficult to ascertain and that six of 14 patients exhibited preexisting severe mental and physical handicaps.
The authors of one of the earlier studies involving 346 patients provided a more comprehensive descriptive narrative and alluded to shunt infections as cause of death. 9 The cause of death at the first operation and at revision
